Research Study

A Phase 3 Open-label Extension (OLE) Study to Evaluate the Long-term Safety and Efficacy of Ralinepag in Subjects With World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH)
Principal Investigator 
John Swiston

Overview

Body Locations and Systems 
Pulmonary Hypertension
ClinicalTrials.gov# 
NCT03683186
Status 
Recruiting
Study Start/End 
Feb 21, 2020 to Sep 30, 2024
Locations 
Diamond Health Care Centre
Name/Title 
Mami Okada, Research Coordinator
Phone 
604-875-4111 ext.69831
Email Address 
mami.okada@vch.ca
Purpose of Study 

This is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.